| 2003 |
- Marketing approval for TS-1 obtained in South Korea
- Inuyama Plant in Aichi Prefecture starts operations
|
|---|
| 2004 |
- Taiho Pharmaceutical signs a licensing agreement for new antiemetic palonosetron with Helsinn Healthcare SA (Switzerland)
- Research results on UFT adjuvant therapy for lung cancer published in New England Journal of Medicine (NEJM)
- Collaboration agreement in oncology signed with the University of Tokushima
|
|---|
| 2005 |
- Taiho Pharmaceutical signs a licensing agreement for anticancer agent Abraxane with American BioSciences Inc.
|
|---|
| 2007 |
- Annex to the head office completed
- Taiho Pharmaceutical holds a ceremony for the 45th anniversary of its founding in Tokyo
- Tenth plant newly established to manufacture anticancer granules and investigational drugs
- Data on TS-1 adjuvant therapy for gastric cancer published in US medical journal, NEJM
|
|---|
| 2008 |
- Otsuka Holdings established
- Results of a phase III trial on combination chemotherapy of TS-1 and cisplatin for advanced gastric cancer (SPIRITS) published in UK medical journal The Lancet Oncology
- Taiho Pharmaceutical of Beijing Co., Ltd., established
|
|---|
| 2009 |
- Marketing approval for TS-1 obtained in China
- Results of adjuvant chemotherapy for breast cancer treatment with UFT (N-SAS-BC01) published in the US’s Journal of Clinical Oncology (JCO)
- Taiho Pharmaceutical and PharmaMar (Spain) enter into a license agreement on anticancer agent, trabectedin
- Taiho History Museum completed at the Tokushima Plant
- Marketing approval obtained in Singapore for TS-ONE (TS-1)
- Taiho Pharmaceutical acquires Tsukuba Research Institute from Banyu Pharmaceutical Co., Ltd
|
|---|
| 2010 |
- Research results from the FIRIS Study published in the digital edition of The Lancet Oncology
- Marketing approval for TS-1 obtained in Taiwan
- Research results for TS-1 on non-small cell lung cancer published in the digital edition of the JCO
|
|---|
| 2011 |
- TS-1 approved in the EU as a treatment for advanced gastric cancer
- Taiho Pharmaceutical signs a licensing agreement on a new antiemetic combination agent with Helsinn Healthcare S.A.
- Taiho Pharmaceutical signs a distribution agreement with MSD K.K. for the anticancer agent vorinostat in Japan
- Taiho Pharmaceutical signs a co-development and commercialization agreement with Nordic Group BV for Teysuno in Europe
- Taiho Pharma Singapore Pte. Ltd. established
|
|---|
| 2012 |
- Marketing of Teysuno begins in Europe
- Masayuki Kobayashi becomes president and representative director
- License agreement for anti-allergy drug bilastine signed with Spain-based Faes Farma S.A.
|
|---|
| 2013 |
- Research results on TS-1 against advanced cancer published in the digital edition of the JCO
- Kitajima Plant completed in Tokushima Prefecture
- Results from a clinical trial of TS-1 in metastaticcolorectal cancer published in the digital edition of The Lancet Oncology
- Agreement signed on transfer of Astellas' fermentation research-related assets to Taiho
|
|---|
| 2014 |
- Name of US-based subsidiary changed from Taiho Pharma U.S.A., Inc. to Taiho Oncology, Inc.
|
|---|
| 2015 |
- Marketing approval for Teysuno obtained in Russia
- Approval obtained from the U.S. FDA for the anticancer drug LONSURF (TAS-102) as a treatment for refractory metastatic colorectal cancer
- Marketing approval for TS-ONE obtained in Myanmar
|
|---|
| 2016 |
- Tiovita 3000 launched in Hong Kong
- Approval for LONSURF obtained in Europe
- TAIHO VENTURES, LLC established in California in the U.S.
- CTM Building (clinical trial materials manufacturing facility) completed at the Kitajima Plant
- TAIHO PHARMA CANADA, INC. established in Canada
|
|---|
